Skip to Content

Notice

Psychopharmacologic Drugs Advisory Committee; Cancellation

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The meeting of the Psychopharmacologic Drugs Advisory Committee scheduled for February 16, 2017, is cancelled. This meeting was announced in the Federal Register of December 27, 2016 (81 FR 95147). The meeting is no longer needed.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Kalyani Bhatt, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-8533, email: PDAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting.

Start Signature

Dated: January 11, 2017.

Janice M. Soreth,

Associate Commissioner for Special Medical Programs.

End Signature End Further Info End Preamble

[FR Doc. 2017-01170 Filed 1-18-17; 8:45 am]

BILLING CODE 4164-01-P